Novavax seeks FDA approval for updated Covid-19 vaccine [Yahoo! Finance]
Novavax, Inc. (NVAX)
Last novavax, inc. earnings: 3/11 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.novavax.com/investor-relations
Company Research
Source: Yahoo! Finance
The company has sought an amendment to its emergency use authorisation to the Covid-19 vaccine. The move aligns with recommendations from the FDA, European Medicines Agency (EMA), and the World Health Organization (WHO) to target the JN.1 lineage for the upcoming fall season. In June 2024 the FDA's Vaccines and Related Biological Products Advisory Committee recommended the development of an updated Covid-19 vaccine to target the JN.1 variant for 2024 to 2025. The JN.1 vaccine by Novavax has shown promising results, with broad cross-neutralising antibodies effective against variant strains including KP.2 and KP.3. These findings suggest the vaccine could offer protection against evolving variants. According to nonclinical studies, Novavax's JN.1 vaccine elicits a comprehensive neutralisation response to JN.1 lineage viruses, including those with the F456L and R346T mutations, and to the variants FLiRT and FLuQE. The updated NVX-CoV2705 specifically targets the parent strain
Show less
Read more
Impact Snapshot
Event Time:
NVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVAX alerts
High impacting Novavax, Inc. news events
Weekly update
A roundup of the hottest topics
NVAX
News
- Free COVID-19 tests are now available. Here's how you can get them. [USA TODAY]USA TODAY
- COVID cases are on a downward trend. How long will this last? [USA TODAY]USA TODAY
- Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & DevelopmentPR Newswire
- Health Canada approves Pfizer's updated COVID-19 vaccine, manufacturer says [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade [Yahoo! Finance]Yahoo! Finance
NVAX
Earnings
- 8/8/24 - Miss
NVAX
Sec Filings
- 9/18/24 - Form 144
- 8/21/24 - Form 4
- 8/20/24 - Form 4
- NVAX's page on the SEC website